Symbio LLC & Dow Development Laboratories LLC have merged with Proinnovera to form Symbio Proinnovera, a dermatology-focused clinical research organization.

The Symbio & Dow Group has a full-service clinical trial CRO offering for dermatology, complemented by a business that is active in the preclinical formulation of topicals, providing services from preclinical formulation work to subsequent clinical trial execution.

Proinnovera is a full-service CRO conducting clinical studies from Phase I to IV, as well as non-interventional and medical device studies. Proinnovera turns study data into oversight for clients to help accelerate decision-making, increase transparency and efficiency in the conduct of clinical trials.

Symbio president Rich Panico, who will become CEO of Symbio Proinnovera said, “I am more than excited to run what will be the leading dermatology CRO in our industry. I have always thought of Symbio and Proinnovera as not only mirror businesses on different continents but also as companies sharing common values. In fact, we wanted this partnership to happen five years ago. It took longer than expected but I am so thrilled it has finally happened.”

Proinnovera Founder and CEO Burkhard Breuer said, “We are delighted to merge with the Symbio Group. Our entities are highly complementary in terms of services, customers, and geographical footprint; we are fully aligned and share the same ultimate objective to elevate clinical trials to the next level.”